Merus Labs International Inc. ("Merus" or the "Company") is pleased to announce that Health Canada has approved its advanced wound care product Collexa®. Collexa® is exclusively licensed to Merus Labs by Innocoll for sales and distribution in Canada.
Collexa is an advanced bilayer wound care device comprising a layer of white collagen matrix with a backing layer of absorbent polyurethane foam. The collagen matrix layer aids in the wound management while the polyurethane foam layer acts as a reservoir absorbing wound fluids. Collexa can absorb greater than ten times its own weight in wound fluids.
Collexa may be used for the management of wounds including: Diabetic ulcers, venous ulcers, pressure ulcers, ulcers caused by mixed vascular etiologies, full thickness & partial thickness wounds, abrasions, traumatic wounds, 1st and 2nd degree burns and surgical wounds. Including Collexa®, Merus currently has 8 wound care products that will be launched in the current quarter. "With the approval of Collexa®, Merus will provide Canadian patients with a stronger pipeline of products designed to greatly advance wound care treatment. We greatly appreciate the diligent work of our partners Innocoll and Methapharm in advancing the approval of Collexa® and launch of our line of wound care products in this quarter." said Ahmad Doroudian, President and CEO.
Protein from gut worms accelerates skin regeneration and reduces scarring